
A weekly injection of tirzepatide lowered body mass index by an average of 18.5 percent in teenagers with obesity over 72 weeks, while teens given a placebo saw their BMI rise slightly, according to a clinical trial published November 15.
The drug, made by Eli Lilly and Co., is already approved for adults with obesity. The results add to the evidence on weight-loss medications for adolescents with weight-related health problems.
What Researchers Found

The trial enrolled 160 participants ages 12 to 17 at 31 sites in the United States, Canada, the Czech Republic, Israel, Italy and Poland.
About two-thirds received tirzepatide and the rest received a placebo. All participants got counseling on diet and physical activity. The average participant was 14.6 years old with a BMI of 38.6.
At 72 weeks, BMI fell 18.5 percent in the tirzepatide group, compared with a 0.5 percent increase in the placebo group.

Nearly 80 percent of teens on the drug cut their BMI by at least 5 percent, versus 28.5 percent on placebo. Some 48.1 percent cut it by at least 20 percent, compared with 7.9 percent.
More than half of those on the drug (53.5 percent) ended the study with a BMI below the 95th percentile, the cutoff for obesity in adolescents. In the placebo group, 7.1 percent did.
Teens on tirzepatide also showed lower blood pressure, improved cholesterol and better blood sugar measures.
What Are the Possible Side Effects?

Digestive problems were the most common. Vomiting affected 50.9 percent of teens on tirzepatide, nausea 50 percent and diarrhea 45.4 percent. The authors wrote that most cases were mild to moderate and occurred more often as doses increased, per reports.
Ten of 108 teens on the drug stopped treatment because of side effects. None in the placebo group did. Serious adverse events occurred in 7.4 percent of those on tirzepatide and 3.9 percent of those on placebo.
Five teens on tirzepatide and one on placebo reported depression or suicidal thoughts as adverse events. The authors said the numbers were low and that every participant who reported suicidal thoughts had a psychiatric history.
They called for close monitoring of mental health in this population. Growth and puberty were similar in both groups.
What Are the Limitations of the Study?

Lilly sponsored the trial and several authors are company employees or shareholders. About 83 percent of participants were white and only one had type 2 diabetes. The authors said longer follow-up is needed.
Four medications, orlistat, liraglutide, semaglutide and phentermine-topiramate, are already approved by the Food and Drug Administration for long-term obesity treatment in adolescents. In an earlier trial, semaglutide reduced BMI by 16.1 percent over 68 weeks.